21 May 2001 Improved low-power semiconductor diode lasers for light activation of pharmaceutical agents
Author Affiliations +
Proceedings Volume 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI; (2001) https://doi.org/10.1117/12.427839
Event: BiOS 2001 The International Symposium on Biomedical Optics, 2001, San Jose, CA, United States
Abstract
In photodynamic therapy, a photosensitizing dye is injected into the patient and the die accumulates in tumor tissue. The cancer cells are then destroyed by absorbing light of a specific wavelength, usually around 630 nm. One of the strong advantages of this therapy is that it destroys only malignant cells and causes less morbidity than standard treatments like surgery and radiotherapy. There are several other techniques that also utilize light activation of pharmaceutical agents in treatment of cancers such as breast cancer. One method of supplying this light activation is through the use of diode lasers, which are constantly finding new application in all fields of medicine. However these lasers tend to be limited by their high cost per watt and multiple wavelength output. Cryogenically cooling such lasers provides higher power output and therefore longer device lifetime. We report quantification of these results from laser power meter and photospectrometer data.
© (2001) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Susanne M. Lee, Eduard K. Mueller, Brian C. Van de Workeen, Otward M. Mueller, "Improved low-power semiconductor diode lasers for light activation of pharmaceutical agents", Proc. SPIE 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI, (21 May 2001); doi: 10.1117/12.427839; https://doi.org/10.1117/12.427839
PROCEEDINGS
8 PAGES


SHARE
Back to Top